LOC100132078: A Drug Target / Disease Biomarker (G100132078)

LOC100132078: A Drug Target / Disease Biomarker

LOC100132078 is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a member of the LOC1001 family of proteins, which are known to play a role in intracellular signaling. LOC100132078 is of particular interest as a potential drug target or biomarker, due to its unique structure and the involvement of intracellular signaling pathways.

The LOC1001 family of proteins are characterized by the presence of a single transmembrane domain and a unique N-terminal region that contains a putative signal- transducing activity. This region is known as the N-terminal hypervariable region (HVR) and is involved in the regulation of protein function. LOC100132078 is a member of the LOC1001 family and is expressed in a variety of tissues, including the brain, heart, and liver.

The N-terminal HVR of LOC100132078 contains a putative GFP-like domain, which is a known signaling domain that is involved in the regulation of protein function. This domain is typically responsible for the production of a signal that can interact with the cytoplasmic protein N-cadherin, which is a protein that is involved in cell-cell adhesion. The N-cadherin-mediated signaling pathway is a well-established intracellular signaling pathway that is involved in the regulation of many cellular processes, including cell growth, differentiation, and survival.

In addition to its involvement in intracellular signaling, LOC100132078 is also of interest as a potential drug target. The N-terminal HVR of LOC100132078 is known to be involved in the regulation of protein function, and this function may be relevant to the development of drug targets. For example, LOC100132078 may be a good candidate for a drug that targets the N-cadherin signaling pathway, as this pathway is involved in the regulation of many cellular processes and may be a useful target for the development of new pharmaceuticals.

Another potential use for LOC100132078 as a drug target is its involvement in the regulation of cell-cell adhesion. As mentioned earlier, LOC100132078 is involved in the N-cadherin signaling pathway, which is responsible for the regulation of cell-cell adhesion. This suggests that LOC100132078 may be a good candidate for a drug that targets cell-cell adhesion, as this process is involved in the regulation of many cellular processes and may be a useful target for the development of new pharmaceuticals.

LOC100132078 is also of interest as a potential biomarker for the diagnosis and prognosis of certain diseases. For example, LOC100132078 may be a good candidate for the diagnosis of neurodegenerative diseases, such as Alzheimer's disease, as this protein is expressed in the brain and is involved in the regulation of intracellular signaling pathways. Additionally, LOC100132078 may be a good candidate for the diagnosis of certain cancers, as this protein is involved in the regulation of intracellular signaling pathways and has been implicated in the development of certain types of cancer.

In conclusion, LOC100132078 is a protein that is expressed in various tissues of the body and is involved in the regulation of intracellular signaling pathways. The N-terminal HVR of LOC100132078 contains a putative GFP-like domain that is involved in the regulation of protein function, and this protein may be of interest as a potential drug target or biomarker. Additionally, LOC100132078 is

Protein Name: Uncharacterized LOC100132078

The "LOC100132078 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC100132078 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC100132249 | LOC100132287 | LOC100132356 | LOC100132609 | LOC100132626 | LOC100132651 | LOC100132686 | LOC100132741 | LOC100132781 | LOC100132797 | LOC100133077 | LOC100133165 | LOC100133177 | LOC100133284 | LOC100133331 | LOC100133920 | LOC100134317 | LOC100134368 | LOC100134391 | LOC100134868 | LOC100190986 | LOC100233156 | LOC100240728 | LOC100240734 | LOC100240735 | LOC100271840 | LOC100272216 | LOC100272217 | LOC100286922 | LOC100287036 | LOC100287290 | LOC100287329 | LOC100287413 | LOC100287792 | LOC100287834 | LOC100287846 | LOC100287944 | LOC100288069 | LOC100288162 | LOC100288208 | LOC100288637 | LOC100288656 | LOC100289230 | LOC100289283 | LOC100289308 | LOC100289333 | LOC100289361 | LOC100289470 | LOC100289473 | LOC100289495 | LOC100289511 | LOC100289561 | LOC100289580 | LOC100289656 | LOC100293211 | LOC100294145 | LOC100335030 | LOC100419773 | LOC100420587 | LOC100421561 | LOC100505498 | LOC100505502 | LOC100505585 | LOC100505664 | LOC100505715 | LOC100505716 | LOC100505841 | LOC100505912 | LOC100505915 | LOC100505978 | LOC100506023 | LOC100506071 | LOC100506076 | LOC100506124 | LOC100506207 | LOC100506236 | LOC100506274 | LOC100506281 | LOC100506379 | LOC100506403 | LOC100506422 | LOC100506444 | LOC100506446 | LOC100506472 | LOC100506474 | LOC100506499 | LOC100506514 | LOC100506532 | LOC100506606 | LOC100506634 | LOC100506639 | LOC100506667 | LOC100506730 | LOC100506974 | LOC100507002 | LOC100507006 | LOC100507053 | LOC100507054 | LOC100507156 | LOC100507165